Chris Rallis - Mar 26, 2024 Form 4 Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Director
Signature
/s/ Chris A. Rallis
Stock symbol
FENC
Transactions as of
Mar 26, 2024
Transactions value $
-$23,191
Form type
4
Date filed
3/27/2024, 04:24 PM
Previous filing
Dec 28, 2023
Next filing
Apr 15, 2024
SEC
View on sec.gov

Transactions Table

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FENC Common Shares Options Exercise -$10K -4.33K -2.31% $2.31 183K Mar 26, 2024 Options 4.24K $2.31 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Shares sold to satisfy tax obligation on option exercise.
F2 Shares acquired through the exercise of an option pusuant to a 10b5-1 plan adopted on August 17, 2023.
F3 Represents options exercised pursuant to a 10b5-1 plan adopted on August 17, 2023.